This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: William Marsh Rice University, Baylor College of Medicine, Houston Methodist Research Institute. Active years: 2022-2025.
Company Filing History:
2 out of 659 
1 out of 617 
1 out of 1 
Years Active: 2022-2025
Title: Innovations by William Sikkema: Pioneering Treatments for Mitochondrial Dysfunction
Introduction
William Sikkema is an innovative inventor based in Langley, Canada. He has made significant contributions to the field of biomedical engineering, particularly in the development of novel therapies for mitochondrial dysfunction and neuronal repair. With a total of two patents to his name, Sikkema's work is at the forefront of addressing oxidative stress and metal-related toxicities in the body.
Latest Patents
Sikkema's latest patents focus on two groundbreaking areas. The first patent addresses treatments for acute and chronic mitochondrial electron transport chain dysfunction. This involves the use of modified hydrophilic carbon clusters (HCCs) and poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs). These materials are designed to facilitate intracellular transport, particularly in mitochondria, and reduce oxidative breakdown of the chelator moiety prior to treatment. This innovative approach aims to mitigate the causes and consequences of metal-induced oxidative stress, providing a novel form of therapy for various toxicities.
The second patent revolves around neuronal scaffold-water soluble graphene for the treatment of severed spinal cords and neuronal repair. This invention utilizes graphene compositions, specifically PEGylated graphene nanoribbons (GNR), in combination with fusogen agents like PEG600. The goal is to enhance neuronal repair and facilitate recovery from spinal cord injuries.
Career Highlights
William S